JP2021501202A5 - - Google Patents

Download PDF

Info

Publication number
JP2021501202A5
JP2021501202A5 JP2020543258A JP2020543258A JP2021501202A5 JP 2021501202 A5 JP2021501202 A5 JP 2021501202A5 JP 2020543258 A JP2020543258 A JP 2020543258A JP 2020543258 A JP2020543258 A JP 2020543258A JP 2021501202 A5 JP2021501202 A5 JP 2021501202A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
alkyl
compound
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020543258A
Other languages
English (en)
Japanese (ja)
Other versions
JP7277473B2 (ja
JP2021501202A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/058050 external-priority patent/WO2019089478A1/en
Publication of JP2021501202A publication Critical patent/JP2021501202A/ja
Publication of JP2021501202A5 publication Critical patent/JP2021501202A5/ja
Priority to JP2023076473A priority Critical patent/JP2023100842A/ja
Application granted granted Critical
Publication of JP7277473B2 publication Critical patent/JP7277473B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020543258A 2017-10-30 2018-10-29 置換フェニルスルホニルフェニルトリアゾールチオンおよびその使用法 Active JP7277473B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023076473A JP2023100842A (ja) 2017-10-30 2023-05-08 置換フェニルスルホニルフェニルトリアゾールチオンおよびその使用法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762579070P 2017-10-30 2017-10-30
US62/579,070 2017-10-30
US201762584630P 2017-11-10 2017-11-10
US62/584,630 2017-11-10
PCT/US2018/058050 WO2019089478A1 (en) 2017-10-30 2018-10-29 Substituted phenyl sulfonyl phenyl triazole thiones and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023076473A Division JP2023100842A (ja) 2017-10-30 2023-05-08 置換フェニルスルホニルフェニルトリアゾールチオンおよびその使用法

Publications (3)

Publication Number Publication Date
JP2021501202A JP2021501202A (ja) 2021-01-14
JP2021501202A5 true JP2021501202A5 (cg-RX-API-DMAC7.html) 2021-11-18
JP7277473B2 JP7277473B2 (ja) 2023-05-19

Family

ID=66333645

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020543258A Active JP7277473B2 (ja) 2017-10-30 2018-10-29 置換フェニルスルホニルフェニルトリアゾールチオンおよびその使用法
JP2023076473A Pending JP2023100842A (ja) 2017-10-30 2023-05-08 置換フェニルスルホニルフェニルトリアゾールチオンおよびその使用法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023076473A Pending JP2023100842A (ja) 2017-10-30 2023-05-08 置換フェニルスルホニルフェニルトリアゾールチオンおよびその使用法

Country Status (12)

Country Link
US (4) US10501423B2 (cg-RX-API-DMAC7.html)
EP (1) EP3703675A4 (cg-RX-API-DMAC7.html)
JP (2) JP7277473B2 (cg-RX-API-DMAC7.html)
KR (1) KR102639231B1 (cg-RX-API-DMAC7.html)
CN (1) CN111372579B (cg-RX-API-DMAC7.html)
AU (1) AU2018359224B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020008727A2 (cg-RX-API-DMAC7.html)
CA (1) CA3080578A1 (cg-RX-API-DMAC7.html)
IL (1) IL274010B2 (cg-RX-API-DMAC7.html)
MX (1) MX2020004202A (cg-RX-API-DMAC7.html)
SG (1) SG11202003879RA (cg-RX-API-DMAC7.html)
WO (1) WO2019089478A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020008727A2 (pt) 2017-10-30 2020-10-20 Neuropore Therapies, Inc. fenil sulfonil fenil triazol tionas substituídas e usos destas
WO2019246454A1 (en) * 2018-06-20 2019-12-26 Neuropore Therapies, Inc. Method of treating a condition associated with neurodegeneration using inhibitors of oat3
CN117384029B (zh) * 2023-12-12 2024-02-20 山东国邦药业有限公司 一种2,4,5-三氟苯乙酸的合成方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1476503A (en) 1973-06-21 1977-06-16 Sterling Drug Inc 1-arylamino-and 1-arylimino-pyrroles and preparation thereof
US4279637A (en) 1979-06-02 1981-07-21 Velsicol Chemical Corporation Herbicidal N-substituted 4-imidazolin-2-ones
DE3307506A1 (de) 1983-03-03 1984-09-06 Agfa-Gevaert Ag, 5090 Leverkusen Fotografisches aufzeichnungsmaterial mit inhibitorvorlaeuferverbindungen
US5108486A (en) * 1990-02-09 1992-04-28 Kanagawa Chemical Laboratory, Ltd. Herbicidal substituted-phenyl-1,2,4-triazol-5(1H)-thiones and -ones
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
DE10123586A1 (de) 2001-05-08 2002-11-28 Schering Ag 3,5-Diamino-1,2,4-triazole als Kinase Inhibitoren
US20020183306A1 (en) 2001-05-30 2002-12-05 Pfizer Inc. Combination treatment for sleep disorders including sleep apnea
RU2223952C2 (ru) 2001-06-04 2004-02-20 Институт физиологически активных веществ РАН Производные n,s-замещенных n'-1-[(гетеро)арил]-n'-[(гетеро)арил]метилизотиомочевин или их солей с фармакологически приемлемыми кислотами нх, способы получения их солей и оснований, фармацевтическая композиция, способ лечения и способ изучения глутаматэргической системы
US20040235877A1 (en) 2001-09-14 2004-11-25 Natsuki Ishizuka Novel use of tricyclic compound
SE0301232D0 (sv) * 2003-04-25 2003-04-25 Astrazeneca Ab Novel use
KR100768609B1 (ko) 2003-07-09 2007-10-18 에프. 호프만-라 로슈 아게 티오페닐아미노이미다졸린
DE10344223A1 (de) 2003-09-24 2005-04-21 Merck Patent Gmbh 1,3-Benzoxazolylderivate als Kinase-Inhibitoren
US20050228031A1 (en) 2004-04-13 2005-10-13 Bilodeau Mark T Tyrosine kinase inhibitors
US7008748B1 (en) * 2004-09-07 2006-03-07 Eastman Kodak Company Silver salt-toner co-precipitates and imaging materials
US7429667B2 (en) 2005-01-20 2008-09-30 Ardea Biosciences, Inc. Phenylamino isothiazole carboxamidines as MEK inhibitors
US20060217390A1 (en) 2005-02-24 2006-09-28 Esmir Gunic Cycloalkl, aryl and heteroaryl amino isothiazoles for the treatment of Hepatitis C virus
AU2006244203B2 (en) 2005-05-09 2012-05-03 Achillion Pharmaceuticals, Inc. Thiazole compounds and methods of use
US20060276464A1 (en) 2005-05-13 2006-12-07 Wyeth Diarylsulfone sulfonamides and use thereof
CA2614098A1 (en) 2005-07-04 2007-01-11 Dr. Reddy's Laboratories Ltd. Thiazoles derivatives as ampk activator
RS53981B1 (sr) 2006-03-24 2015-10-30 Array Biopharma Inc. Analozi 2-aminopiridina kao aktivatori glukokinaze
MX2009004947A (es) 2006-11-09 2009-05-19 Hoffmann La Roche Arilsulfonil-pirrolidinas como inhibidores 5-hidroxitriptaminas6 (5-ht6).
JP5442449B2 (ja) 2006-12-22 2014-03-12 アステックス、セラピューティックス、リミテッド 新規化合物
JP5450108B2 (ja) 2007-03-23 2014-03-26 アレイ バイオファーマ、インコーポレイテッド グルコキナーゼ活性化剤としての2−アミノピリジン類似体
EA019104B1 (ru) 2007-09-21 2014-01-30 Эррей Биофарма Инк. Активаторы глюкокиназы
TW200940542A (en) 2008-01-09 2009-10-01 Array Biopharma Inc Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US9271962B2 (en) 2008-03-17 2016-03-01 Northeastern University Inhibitors of fatty acid amide hydrolase and monoacylglycerol lipase for modulation of cannabinoid receptors
CA2753158A1 (en) 2009-02-23 2010-08-26 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to cd19 and their uses
KR102142753B1 (ko) 2009-03-27 2020-09-14 히타치가세이가부시끼가이샤 열경화성 수지 조성물, 및 이를 이용한 프리프레그, 지지체 부착 절연 필름, 적층판 및 인쇄 배선판
UY32582A (es) 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
JP2013501064A (ja) 2009-08-04 2013-01-10 アミラ ファーマシューティカルス,インコーポレーテッド リゾホスファチジン酸受容体アンタゴニストとしての化合物
US8962631B2 (en) 2010-05-12 2015-02-24 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
CN106986856A (zh) 2010-09-03 2017-07-28 福马Tm有限责任公司 作为用于治疗疾病诸如癌症的nampt抑制剂的4‑{[(吡啶‑3‑基‑甲基)氨基羰基]氨基}苯‑砜衍生物
EP2814846B1 (en) 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
CN104334547B (zh) 2012-05-22 2017-06-06 奥蒂福尼疗法有限公司 作为kv3抑制剂的三唑类
US20140044813A1 (en) 2012-08-09 2014-02-13 Kemin Industries, Inc. Plant Extracts for Improving Cognitive Health and Function
JP2015524483A (ja) * 2012-08-09 2015-08-24 ニューロポア セラピーズ,インコーポレイティド Pi3−キナーゼシグナリング経路の調節因子としてのアリール及びヘテロアリールで置換されたベンゼン誘導体
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
BR112020008727A2 (pt) 2017-10-30 2020-10-20 Neuropore Therapies, Inc. fenil sulfonil fenil triazol tionas substituídas e usos destas

Similar Documents

Publication Publication Date Title
JP2022547558A5 (cg-RX-API-DMAC7.html)
KR102216381B1 (ko) 에다라본 및 (+)-2-보르네올의 설하 약학 조성물
KR102663478B1 (ko) 에다라본 약제학적 조성물
AU2017326791A1 (en) Medicinal composition
JP2019510787A5 (cg-RX-API-DMAC7.html)
WO2017140254A1 (zh) 一种含有jak激酶抑制剂或其可药用盐的药物组合物
TWI884912B (zh) 喹啉酮類似物及其鹽、組合物及其使用方法
KR20170081228A (ko) 티족사나이드, 그의 유사체 또는 염의 전구 약물을 이용한 치료 조성물 및 방법
TW201501730A (zh) 用於口服投藥之包含非晶型托伐普坦(Tolvaptan)的懸浮液
JP7617898B2 (ja) Eyp001を使用した改善された処置
JP2019501879A5 (cg-RX-API-DMAC7.html)
US20150064252A1 (en) Solid dispersion formulation of an antiviral compound
KR20220146496A (ko) 뉴클레오티드계 화합물의 코로나 바이러스 감염증의 치료에의 사용
JP2022514569A5 (cg-RX-API-DMAC7.html)
CA3154120A1 (en) Combination treatment with a p53 reactivator and an inhibitor of an antiapoptotic bcl-2 family protein
WO2012087257A2 (en) Oral dosage form comprising imatinib and production of said oral dosage form
JP2023533162A5 (cg-RX-API-DMAC7.html)
KR20180071276A (ko) Hcv 치료를 위한 조합물 요법 투약법
KR101282847B1 (ko) 실로스타졸을 함유하는 고체분산체 및 이를 포함하는 약학 조성물
JP2017505313A5 (cg-RX-API-DMAC7.html)
JP5932829B2 (ja) 経口活性ヌクレオチドアナログ又は経口活性ヌクレオチドアナログプロドラッグの高度に安定な組成物
JP2022548616A5 (cg-RX-API-DMAC7.html)
FI4027973T3 (fi) Lääkkeensaattoformulaatioita
JP2019516765A5 (cg-RX-API-DMAC7.html)
RU2018142381A (ru) Фармацевтический препарат